SCHEMBL196586

SCHEMBL196586

NC(NC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 1/20 0.65
LMNA P02545 2/20 0.50
HPGD P15428 2/20 0.50
HDAC3 O15379 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
IDO1 P14902 1/20 0.50
ALOX15 P16050 1/20 0.50
HDAC1 Q13547 1/20 0.50
CA9 Q16790 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
CTRB1 P17538 4/20 0.49
ALDH1A1 P00352 3/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29408688 1.00 SLC1A2 (0.65) SLC1A2LMNAHPGDHDAC3CA12
Hydrochloric Acid SCHEMBL27406623 0.98 SLC1A2 (0.62) SLC1A2LMNAHPGDHDAC3CA12
SCHEMBL28193079 0.98 SLC1A2 (0.62) SLC1A2LMNAHPGDHDAC3CA12
SCHEMBL27726231 0.84 SMN1; SMN2 (0.54) SLC1A2LMNAHPGDCA1ALDH1A1
SCHEMBL12262967 0.83 SLC1A2 (0.63) SLC1A2LMNAHPGDHDAC3CA12
SCHEMBL27529872 0.83 SLC1A2 (0.63) SLC1A2LMNAHPGDHDAC3CA12
SCHEMBL8965153 0.82 SLC1A2 (0.46) SLC1A2CA1HDAC2POLBMAPT
SCHEMBL233365 0.82 SLC1A2 (0.54) SLC1A2LMNAHPGDHDAC3CA12
Aminohippuric Acid SCHEMBL29414543 0.81 KDM4E (0.68) SLC1A2LMNACA1HDAC1HDAC6
SCHEMBL21232958 0.79 SLC1A2 (0.59) SLC1A2LMNAHPGDHDAC3CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 820 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
CN-119350093-A Preparation method of slow-release urea and application of slow-release urea in saline-alkali soil remediation 西北师范大学 2025-01-24 CN claimed
US-20240390364-A1 Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions REID CHRISTOPHER BRIAN (US) 2024-11-28 US claimed
US-20230158041-A1 METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-05-25 US claimed
US-20230074763-A1 IDENTIFICATION OF HOST-TARGETING MODULATORS OF BACTERIAL UPTAKE AND ASSAY FOR QUANTIFYING INTRACELLULAR BACTERIA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2023-03-09 US claimed
EP-3965751-B1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE ITM ISOTOPE TECH MUNICH SE (DE) 2022-12-28 EP claimed
WO-2022096103-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotopen Technologien München AG (DE) 2022-05-12 WO claimed
CN-114126654-A Para-aminohippuric acid (PAH) as a kidney protective substance 同位素技术慕尼黑有限公司 2022-03-01 CN claimed
US-20210331145-A1 HYDROGENATION PROCESS COMPRISING A CATALYST PREPARED BY ADDITION OF AN ORGANIC COMPOUND IN THE GAS PHASE IFP Energies Nouvelles (FR) 2021-10-28 US claimed
EP-2459227-B1 Prodrugs containing an aromatic amine connected by an amide bond to a carrier ASCENDIS PHARMA AS (DK) 2021-03-17 EP claimed
US-20080306025-A1 N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE YU RUEY J 2008-12-11 US claimed
EP-1979366-A2 N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE Yu, Ruey J. (US) 2008-10-15 EP claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007087013-A2 FUNCTIONAL IMMUNOASSAY BIOPAL, INC. (US) 2007-08-02 WO claimed
WO-2007082206-A2 N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE YU RUEY J (US) 2007-07-19 WO claimed
US-20070161543-A1 N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE YU RUEY J 2007-07-12 US claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-7176185-B2 Short peptide carrier system for cellular delivery of agent TSRL, INC. (US) 2007-02-13 US claimed
US-20050137141-A1 Prodrug composition HILFINGER JOHN (US) 2005-06-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230158041-A1 METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ABCC3, HTR3A, PKD1 SLC1A2 963/4885LMNA 2471/4885HPGD 2138/4885
US-20050137141-A1 Prodrug composition CYP3A5, SLC35B2, SLC1A5 SLC1A2 106/4885LMNA 3095/4885HPGD 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.